Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism — ZEST-PREP  

Thyrotoxicosis Clinical Trial

Official title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism

Status Not yet recruiting

Clinical Trial Summary

This randomized, double-blind, placebo-controlled trial evaluates the efficacy of a zinc, selenium, and L-tyrosine supplement in preventing thyrotoxicosis among adults aged 18-85 with elevated TPOAb levels and the r25191G/A SEPP1 polymorphism. The study excludes those with thyroid disease, pregnant/breastfeeding women, and individuals allergic to the supplement. Key endpoints include changes in thyroid antibodies and hormones over a 6-month period. With an estimated sample size of 150 participants per group, accounting for a 20% dropout rate, the trial seeks to demonstrate the supplement's potential in reducing thyrotoxicosis risk through a genetically-informed approach.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Thyrotoxicosis

• NCT number: NCT06264544
• Study type: Interventional
• Source: S.LAB (SOLOWAYS)
• Contact: Andrey V Ponomarenko, MD
• Phone: 9628316017
• Email: dasyshadoff@gmail.com
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 30, 2024
• Completion date: December 30, 2024